C. Z. Chen

Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, A Potential Oral Drug Candidate for COVID-19 Treatment

This study examines the preclinical pharmacokinetics and in vitro ADME properties of GS-441524, showing its stability across species and varying bioavailability, supporting its development as an oral drug candidate for COVID-19.

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

The paper develops and validates a series of assays to identify TMPRSS2 inhibitors as potential COVID-19 treatments, identifying six compounds with varying clinical statuses.

Camel nanobodies broadly neutralize SARS-CoV-2 variants

The paper isolates two camel nanobodies that broadly neutralize SARS-CoV-2 and its variants, showing therapeutic potential in mice.

Mitoxantrone modulates a glycosaminoglycan-spike complex to inhibit SARS-CoV-2 infection

This study shows Mitoxantrone inhibits SARS-CoV-2 infection by targeting the spike-GAG complex, but also affects nucleosome dynamics.

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry

This paper develops a high throughput screening assay using SARS-CoV-2 pseudotyped particles to identify inhibitors of viral entry, finding 7 active compounds effective against both pseudotyped particles and live virus.

A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening

The paper develops a TR-FRET assay for SARS-CoV-2 NP detection, enabling high-throughput screening of compounds against SARS-CoV-2 and its variants.

A hybrid in silico approach reveals novel inhibitors of multiple SARS-CoV-2 variants

The paper uses a hybrid in silico approach combining machine learning and pharmacophore modeling on NCATS screening data to identify novel inhibitors effective against multiple SARS-CoV-2 variants.

Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid

This paper develops a high-throughput AlphaLISA assay to detect SARS-CoV-2 nucleocapsid protein, enabling screening of antiviral compounds.

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2

The paper identifies 319 compounds with anti-SARS-CoV-2 activities through a high-throughput screen, including 91 approved drugs and 49 investigational drugs, with 230 compounds previously unreported.

Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2

This paper develops a biological activity-based modeling approach to identify novel antiviral compounds against SARS-CoV-2 with high hit rates in live virus assays.

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening

This study identifies 23 SARS-CoV-2 3CLpro inhibitors through high-throughput screening, with several showing potent activity against viral infection.

Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles

This paper identifies six broad-spectrum inhibitors of SARS-CoV-2 and MERS-CoV spike-mediated cell entry through drug repurposing screens using pseudotyped particles.

Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research

This paper describes the NCATS OpenData Portal, a platform for real-time sharing of drug screening data that accelerates translational research by enabling immediate access to large-scale datasets.

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators

The paper identifies six autophagy modulators that block SARS-CoV-2 cytopathic effects in Vero-E6 cells with EC50 values between 2.0 and 13 µM.